The United Kingdom and the United States have announced a important bilateral deal that will preserve no tariffs on British medicine shipments going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on pharmaceuticals through the National Health Service (NHS). This move guarantees that tariffs on these crucial goods will remain at nothing for a period of 36 months.
This deal is in response to recent threats to hike duties on patented pharmaceutical products, with potential rates discussed as high as one hundred percent.
"This arrangement between the Britain bolsters the international landscape for cutting-edge drugs and brings much-needed equity to American-British medicine commerce," a statement declared.
Trade Importance
Drugs are one of the UK's biggest goods shipped to the United States, which is by far the largest destination for major British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to last September, the UK shipped drugs valued at over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This guarantee protects employment, stimulates funding and facilitates the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The pact involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to raise total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped twenty percent.
Recent Tensions
The pact follows a protracted tension between the sector and the ministers over spending levels and NHS adoption.
This friction were exacerbated by claims that US consumers were paying significantly more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its resources over the previous ten-year period.
